- Home
- ECBK vs VERU Comparison
ECBK vs VERU Comparison
Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- VERU
- Stock Information
- Founded
- ECBK 1919
- VERU 1971
- Country
- ECBK United States
- VERU United States
- Employees
- ECBK N/A
- VERU N/A
- Industry
- ECBK Banks
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- VERU Health Care
- Exchange
- ECBK Nasdaq
- VERU Nasdaq
- Market Cap
- ECBK 123.9M
- VERU 113.1M
- IPO Year
- ECBK N/A
- VERU 1990
- Fundamental
- Price
- ECBK $14.38
- VERU $0.77
- Analyst Decision
- ECBK
- VERU Strong Buy
- Analyst Count
- ECBK 0
- VERU 4
- Target Price
- ECBK N/A
- VERU $4.00
- AVG Volume (30 Days)
- ECBK 13.0K
- VERU 460.0K
- Earning Date
- ECBK 11-07-2024
- VERU 08-08-2024
- Dividend Yield
- ECBK N/A
- VERU N/A
- EPS Growth
- ECBK 74.17
- VERU N/A
- EPS
- ECBK 0.42
- VERU N/A
- Revenue
- ECBK $24,752,000.00
- VERU $14,091,909.00
- Revenue This Year
- ECBK N/A
- VERU N/A
- Revenue Next Year
- ECBK N/A
- VERU N/A
- P/E Ratio
- ECBK $34.15
- VERU N/A
- Revenue Growth
- ECBK 2.68
- VERU N/A
- 52 Week Low
- ECBK $9.82
- VERU $0.36
- 52 Week High
- ECBK $14.84
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- ECBK 58.93
- VERU 41.80
- Support Level
- ECBK $14.28
- VERU $0.73
- Resistance Level
- ECBK $14.84
- VERU $0.80
- Average True Range (ATR)
- ECBK 0.38
- VERU 0.04
- MACD
- ECBK 0.02
- VERU -0.00
- Stochastic Oscillator
- ECBK 72.94
- VERU 44.33
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.